日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

PRABITAS study design: a pragmatic, randomized phase III trial of bi-weekly versus conventional trifluridine/tipiracil plus bevacizumab for metastatic colorectal cancer

PRABITAS 研究设计:一项务实的随机 III 期临床试验,比较每两周一次的三氟尿苷/替吡嘧啶联合贝伐珠单抗与常规方案治疗转移性结直肠癌的疗效。

Sakakida, T; Masuishi, T; Asayama, M; Mitani, S; Makiyama, A; Shimura, T; Takeda, H; Suwa, Y; Takano, Y; Sawada, K; Yomoda, T; Mushiake, H; Okumura, Y; Yokota, M; Yamamoto, M; Kito, Y; Ogawa, K; Matsuoka, H; Ando, M; Tajika, M; Muro, K; Kudo, C; Mishima, A; Murotani, K; Taniguchi, H

Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16

Ramucirumab联合FOLFIRI方案作为既往接受过抗EGFR抗体治疗的RAS野生型转移性结直肠癌患者的二线治疗:JACCRO CC-16

Yasui, H; Okita, Y; Nakamura, M; Sagawa, T; Watanabe, T; Kataoka, K; Manaka, D; Shiraishi, K; Akazawa, N; Okuno, T; Shimura, T; Shiozawa, M; Sunakawa, Y; Ota, H; Kotaka, M; Okuyama, H; Takeuchi, M; Ichikawa, W; Fujii, M; Tsuji, A

Tropomyosin-related receptor kinase B at the invasive front and tumour cell dedifferentiation in gastric cancer.

胃癌侵袭前沿的肌球蛋白相关受体激酶 B 和肿瘤细胞去分化

Tanaka K, Shimura T, Kitajima T, Kondo S, Ide S, Okugawa Y, Saigusa S, Toiyama Y, Inoue Y, Araki T, Uchida K, Mohri Y, Kusunoki M

Enhancement of autophagy is a potential modality for tumors refractory to radiotherapy

增强自噬是治疗放射治疗耐药肿瘤的一种潜在方法

Kuwahara, Y; Oikawa, T; Ochiai, Y; Roudkenar, M H; Fukumoto, M; Shimura, T; Ohtake, Y; Ohkubo, Y; Mori, S; Uchiyama, Y; Fukumoto, M

BCL6 degradation caused by the interaction with the C-terminus of pro-HB-EGF induces cyclin D2 expression in gastric cancers

与 pro-HB-EGF C 端相互作用引起的 BCL6 降解诱导胃癌中的细胞周期蛋白 D2 表达

Y Hirata, N Ogasawara, M Sasaki, T Mizushima, T Shimura, T Mizoshita, Y Mori, E Kubota, T Wada, S Tanida, H Kataoka, T Kamiya, S Higashiyama, T Joh